Ozempic being a household name, GLP-1 receptor agonists (GLP-1RAs), a class of medications have garnered significant ...

In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...

Taking a GLP-1 may help treat sleep apnea since obesity is one of many factors that increases your likelihood of the sleep ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Clinics in Columbus, Cleveland, Dayton, and Cincinnati have lost their licenses to distribute dangerous drugs after the Ohio ...

Dr. Altagrace Hanley, medical director at La Boussole Medical Spa & Wellness Center, has achieved board certification in obesity medicine. La Boussole's program includes advanced options such as GLP-1 ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. Read more here.

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

including the clinical study on the combination of the Allurion Program with GLP-1 agonists, (iii) the evolution of the markets in which Allurion competes and the rise of GLP-1 drugs, (iv) the ability ...